Kodu・Aktsiate loetelu・Galectin Therapeutics Inc

Galectin Therapeutics Inc

Suletud

SektorTervishoid

2.97 -1

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

2.94

Max

3.16

Põhinäitajad
By Trading Economics
Sissetulek	454K -5M
Aktsiakasum	-0.08
Töötajad	9
EBITDA	474K -3M

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+270.37% upside

Dividendid
By Acuity
Järgmine tulemuste avaldamine	12. aug 2026

Turustatistika
By TradingEconomics
Turukapital	77M 223M
Eelmine avamishind	3.97
Eelmine sulgemishind	2.97

Uudiste sentiment

By Acuity

25%

75%

73 / 340 Pingereas Healthcare

Galectin Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

3. aug 2026, 19:46 UTC

Galectin Therapeutics Inc is higher today, continuing an upward trend since Friday's close, despite pulling back from a session high. No specific news was identified.

31. juuli 2026, 21:51 UTC

Galectin Therapeutics Inc is lower in after-market trading, influenced by broader market trends. The asset has faced three consecutive sessions of declines.

30. juuli 2026, 20:10 UTC

Galectin Therapeutics Inc is lower today, breaking a trend of higher daily closes. Increased market volume accompanies the decline amid broader market volatility.

29. juuli 2026, 18:58 UTC

Galectin Therapeutics Inc shares are higher today, continuing an upward trend since Tuesday's close. The stock remains below its 20-day moving average.

28. juuli 2026, 17:46 UTC

Galectin Therapeutics Inc shares are lower today, continuing a decline since Monday's close, amid broader market caution following significant drops in Asian indices.

27. juuli 2026, 16:32 UTC

Galectin Therapeutics Inc shares are lower today, reflecting a notable decline since Friday. The stock has seen unusually high trading volume amid broader market sentiment.

24. juuli 2026, 20:02 UTC

Galectin Therapeutics Inc is lower today, marking its ninth consecutive session of declines. The stock remains below its 20-day moving average.

22. juuli 2026, 19:01 UTC

Galectin Therapeutics Inc. shares are trading lower, following a peak earlier in the session. High trading volume indicates increased investor activity.

21. juuli 2026, 17:16 UTC

Galectin Therapeutics Inc. shares are lower today, continuing a five-session decline and trading significantly below the 20-day moving average. No specific news was identified.

20. juuli 2026, 20:06 UTC

Galectin Therapeutics Inc shares are lower today, continuing a trend of five consecutive daily declines amid broader market volatility linked to geopolitical tensions.

Võrdlus sarnastega

Hinnamuutus

Galectin Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

270.37% tõus

12 kuu keskmine prognoos

Keskmine 11 USD 270.37%

Kõrge 11 USD

Madal 11 USD

Põhineb 1 Wall Streeti analüütiku instrumendi Galectin Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

1 ratings

Osta

Hoia

Müü

Põhineb 1 analüütiku instrumendi Galectin Therapeutics Inc aktsia reitingul - viimase 3 kuu andmed.

Sentiment

By Acuity

73 / 340 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Galectin Therapeutics Inc

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.